Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Teva
Covington
Dow
Moodys
Baxter
QuintilesIMS
McKesson
UBS

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,575,757

« Back to Dashboard

Which drugs does patent 7,575,757 protect, and when does it expire?

Patent 7,575,757 protects ORAVERSE and is included in one NDA.

This patent has fifteen patent family members in twelve countries.
Summary for Patent: 7,575,757
Title:Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Abstract:The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
Inventor(s): Chen; Andrew X. (San Diego, CA), Knowles; Julius (Del Mar, CA), Weber; Eckard (San Diego, CA)
Assignee: Novalar Pharmaceuticals, Inc. (San Diego, CA)
Application Number:11/082,968
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use; Dosage form;

Drugs Protected by US Patent 7,575,757

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,575,757

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,229,630 Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof ➤ Try a Free Trial
7,569,230 Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,575,757

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003247568 ➤ Try a Free Trial
Brazil 0311965 ➤ Try a Free Trial
Canada 2489526 ➤ Try a Free Trial
China 100391460 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Colorcon
Healthtrust
Johnson and Johnson
Chinese Patent Office
Daiichi Sankyo
Dow
Chubb
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.